SCHEMBL3010503

SCHEMBL3010503

Cc1ccc(C)c(Cc2csc(N3CCN(S(=O)(=O)c4cccc(Cl)c4Cl)CC3)n2)c1

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.43
SMN1; SMN2 Q16637 3/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
RAB9A P51151 1/20 0.41
MAPT P10636 2/20 0.41
TP53 P04637 2/20 0.41
TSHR P16473 1/20 0.41
LMNA P02545 4/20 0.41
KMT2A Q03164 3/20 0.41
MEN1 O00255 2/20 0.39
KDM4E B2RXH2 1/20 0.38
POLB P06746 1/20 0.38
CNR1 P21554 1/20 0.37
CNR2 P34972 1/20 0.37
MAPK1 P28482 1/20 0.37
USP2 O75604 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3007799 0.93 ALDH1A1 (0.43) ALDH1A1SMN1; SMN2L3MBTL1RAB9AMAPT
SCHEMBL3015479 0.90 LMNA (0.43) ALDH1A1SMN1; SMN2RAB9AMAPTTP53
SCHEMBL3015983 0.87 LPAR1 (0.42) ALDH1A1SMN1; SMN2L3MBTL1RAB9AMAPT
SCHEMBL3008933 0.87 LMNA (0.44) ALDH1A1SMN1; SMN2L3MBTL1RAB9AMAPT
SCHEMBL3013687 0.87 KMT2A (0.42) ALDH1A1SMN1; SMN2L3MBTL1MAPTTP53
SCHEMBL3015990 0.87 TSHR (0.42) ALDH1A1SMN1; SMN2L3MBTL1RAB9AMAPT
SCHEMBL3014116 0.87 MAPT (0.44) ALDH1A1SMN1; SMN2L3MBTL1RAB9AMAPT
SCHEMBL3002483 0.87 ALDH1A1 (0.41) ALDH1A1SMN1; SMN2L3MBTL1RAB9AMAPT
SCHEMBL2998544 0.87 TSHR (0.44) ALDH1A1SMN1; SMN2MAPTTP53TSHR
SCHEMBL3020861 0.87 CTSS (0.40) SMN1; SMN2RAB9AMAPTTP53LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA ALDH1A1 3510/4885SMN1; SMN2 1/4885L3MBTL1 1847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.